Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment

Title: ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment
Authors: Bochicchio M. T.; Marconi G.; Baldazzi C.; Bandini L.; Ruggieri F.; Lucchesi A.; Agostinelli C.; Sabattini E.; Orsatti A.; Ferrari A.; Capirossi G.; Servili C.; Ghelli Luserna di Rora A.; Martinelli G.; Simonetti G.; Rosti G.
Contributors: Bochicchio M.T.; Marconi G.; Baldazzi C.; Bandini L.; Ruggieri F.; Lucchesi A.; Agostinelli C.; Sabattini E.; Orsatti A.; Ferrari A.; Capirossi G.; Servili C.; Ghelli Luserna di Rora A.; Martinelli G.; Simonetti G.; Rosti G.
Publication Year: 2024
Collection: IRIS Università degli Studi di Bologna (CRIS - Current Research Information System)
Subject Terms: diagnostic RNA panel; ETV6::ABL1; fusion gene; imatinib mesylate; myeloid/lymphoid neoplasm; next generation sequencing
Description: ETV6::ABL1 rearranged neoplasms are rare hematological diseases. To date, about 80 cases have been reported, including myeloid and lymphoid leukemias. The ETV6 gene codes for an ETS family transcription factor and several fusion partners have been described. When translocated, ETV6 causes the constitutive activation of the partner genes. Here, we report the case of a 54-year-old woman with a cryptic insertion of the 3′ region of ABL1 in the ETV6 gene. The patient was first diagnosed with idiopathic hypereosinophilic syndrome, according to the clinical history, conventional cytogenetics, standard molecular analyses and pathologist description. Next generation sequencing of diagnosis samples unexpectedly detected both ETV6::ABL1 type A and B fusion transcripts, which were then confirmed by FISH. The diagnosis was Myeloid/Lymphoid neoplasm with ETV6::ABL1 fusion, and the patient received imatinib mesylate treatment. In a follow-up after more than one year, the patient still maintained the molecular and complete hematological responses. This case highlights the importance of timely and proper diagnostics and prompt tyrosine kinase inhibitor treatment.
Document Type: article in journal/newspaper
File Description: ELETTRONICO
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/38203288; info:eu-repo/semantics/altIdentifier/wos/WOS:001141507700001; volume:25; issue:1; firstpage:0; lastpage:0; numberofpages:1; journal:INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; https://hdl.handle.net/11585/954656
DOI: 10.3390/ijms25010118
Availability: https://hdl.handle.net/11585/954656; https://doi.org/10.3390/ijms25010118; https://www.mdpi.com/1422-0067/25/1/118
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.4D13C881
Database: BASE